H. Vanderstichele

P. Riederer, C. Hock, Khadija Iqbal, 2005, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Increased Abeta1-42 production sensitizes neuroblastoma cells for ER stress toxicity.

F. Baas, H. Vanderstichele, W. Scheper, 2008, Current Alzheimer research.

Highly specific and ultrasensitive plasma test detects Abeta(1–42) and Abeta(1–40) in Alzheimer’s disease

W. M. van der Flier, P. Scheltens, H. Vanderstichele, 2021, Scientific reports.

Growth‐associated protein 43 in lesions and cerebrospinal fluid in multiple sclerosis

F. Barkhof, C. Polman, H. Vanderstichele, 2006, Neuropathology and applied neurobiology.

The Cerebrospinal Fluid Levels of Tau, Growth-Associated Protein-43 and Soluble Amyloid Precursor Protein Correlate in Alzheimer’s Disease, Reflecting a Common Pathophysiological Process

K. Blennow, H. Vanderstichele, E. Vanmechelen, 2001, Dementia and Geriatric Cognitive Disorders.

Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein

Hugo Vanderstichele, Wim Annaert, H. Vanderstichele, 1998, Nature.

Machine learning for comprehensive forecasting of Alzheimer’s Disease progression

Jonathan R. Walsh, Aaron M. Smith, Charles K. Fisher, 2018, Scientific Reports.

Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis

H. Vanderstichele, R. Vandenberghe, R. Bruffaerts, 2020, Alzheimer's Research & Therapy.

Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer's Disease.

K. Blennow, H. Vanderstichele, R. Martins, 2019, Journal of Alzheimer's disease : JAD.

Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease

Blaine R. Roberts, Joanne S. Robertson, C. Rowe, 2014, Alzheimer's & Dementia.

Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI

C. Jack, C. DeCarli, M. Weiner, 2011, Acta Neuropathologica.

The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau

Christopher J. Weber, K. Blennow, M. Carrillo, 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years.

K. Blennow, H. Vanderstichele, E. Vanmechelen, 2007, Journal of Alzheimer's disease : JAD.

Assessing the commutability of reference material formats for the harmonization of amyloid-β measurements

K. Blennow, L. Shaw, H. Vanderstichele, 2016, Clinical chemistry and laboratory medicine.

Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.

Harald Hampel, Wiesje M van der Flier, Philip Scheltens, 2015, Brain : a journal of neurology.

Effect of tamoxifen on the activity of enzymes of testicular steroidogenesis

H. Vanderstichele, I. Leusen, W. Eechaute, 1989, Steroids.

Potential sources of interference on Abeta immunoassays in biological samples

H. Vanderstichele, E. Vanmechelen, A. Jeromin, 2012, Alzheimer's Research & Therapy.

A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid

H. Vanderstichele, B. Mollenhauer, E. Vanmechelen, 2016, PloS one.

Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer’s Disease

H. Vanderstichele, H. Struyfs, S. Engelborghs, 2016, Journal of Alzheimer's disease : JAD.

Transferring cut-off values between assays for cerebrospinal fluid Alzheimer's disease biomarkers.

H. Vanderstichele, T. Burzykowski, E. Coart, 2015, Journal of Alzheimer's disease : JAD.

Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease

K. Blennow, H. Vanderstichele, R. Martins, 2020, Translational Psychiatry.

An in vitro model for the study of microglia-induced neurodegeneration: involvement of nitric oxide and tumor necrosis factor-α

H. Vanderstichele, E. Vanmechelen, L. Fransen, 2001, Neurochemistry International.

Cerebrospinal Fluid Beta-Amyloid 42 Is Reduced before the Onset of Sporadic Dementia: A Population-Based Study in 85-Year-Olds

K. Blennow, H. Vanderstichele, E. Vanmechelen, 2003, Dementia and Geriatric Cognitive Disorders.

Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.

Chengjie Xiong, Andrei G. Vlassenko, David M Holtzman, 2015, JAMA neurology.

Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI

Robert A. Dean, Leslie M. Shaw, John Q. Trojanowski, 2011, Acta Neuropathologica.

CSF Aβ1-42 - an excellent but complicated Alzheimer's biomarker - a route to standardisation.

K. Blennow, L. Shaw, M. Korecka, 2017, Clinica chimica acta; international journal of clinical chemistry.

Relevance of Aβ42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLMR Scale

H. Vanderstichele, S. Lehmann, E. Vanmechelen, 2018, Front. Aging Neurosci..

The effects of neonatal androgenization of male rats on testosterone metabolism by the hypothalamus-pituitary-gonadal axis.

H. Vanderstichele, I. Leusen, W. Eechaute, 1987, Journal of steroid biochemistry.

In vitro maturation of bovine oocytes in the presence of bovine activin A does not affect the number of embryos.

H. Vanderstichele, B. Colenbrander, E. Zeinstra, 1996, Animal reproduction science.

Antibody‐based methods for the measurement of α‐synuclein concentration in human cerebrospinal fluid – method comparison and round robin study

K. Blennow, L. Shaw, H. Vanderstichele, 2018, Journal of neurochemistry.

The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review

A. Fagan, K. Blennow, J. Molinuevo, 2018, Alzheimer's & Dementia.

A user's guide for α‐synuclein biomarker studies in biological fluids: Perianalytical considerations

D. Selkoe, D. Galasko, H. Vanderstichele, 2017, Movement disorders : official journal of the Movement Disorder Society.

Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.

J. Trojanowski, L. Shaw, H. Vanderstichele, 2012, Methods.

CSF Aβ1-42-an excellent but complicated Alzheimer biomarker-the IFCC WG-CSF route to standardisation

Ingrid, K. Blennow, L. Shaw, 2018 .

Validation of assays for measurement of amyloid-β peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab.

H. Vanderstichele, R. Dean, R. Demattos, 2013, Journal of Alzheimer's disease : JAD.

Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke

K. Blennow, H. Vanderstichele, E. Vanmechelen, 2001, Neuroscience Letters.

Ex vivo18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway

K. Blennow, H. Vanderstichele, H. Zetterberg, 2017, Molecular Neurodegeneration.

Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.

Anders Wallin, Björn Holmberg, Annika Olsson, 2005, Clinical chemistry.

Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt–Jakob disease from other dementias

H. Vanderstichele, Hans Förstl, A. Kurz, 2003, Molecular Psychiatry.

Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice.

P. Scheltens, H. Vanderstichele, A. Kok, 2005, Clinical chemistry.

Standardization of measurement of β-amyloid(1-42) in cerebrospinal fluid and plasma

K. Blennow, H. Vanderstichele, L. Minthon, 2000, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

Phosphorylated tau in cerebrospinal fluid as a marker for Creutzfeldt–Jakob disease

H. Vanderstichele, E. Vanmechelen, P. Cras, 2002, Journal of neurology, neurosurgery, and psychiatry.

Added diagnostic value of CSF biomarkers in differential dementia diagnosis

P. Deyn, H. Vanderstichele, S. Engelborghs, 2010, Neurobiology of Aging.

Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia

P. Deyn, H. Vanderstichele, S. Engelborghs, 2008, Neurobiology of Aging.

Effect of the micro-environment on α-synuclein conversion and implication in seeded conversion assays

H. Vanderstichele, I. Zerr, F. Llorens, 2020, Translational Neurodegeneration.

Effect of the micro-environment on α-synuclein conversion and implication in seeded conversion assays

H. Vanderstichele, I. Zerr, F. Llorens, 2020, Translational Neurodegeneration.

Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies

K. Blennow, H. Vanderstichele, H. Hampel, 2006, Clinical chemistry and laboratory medicine.

Neurotoxicity marker profiles in the CSF are not age-dependent but show variation in children treated for acute lymphoblastic leukemia.

H. Vanderstichele, E. Vanmechelen, A. Van de Voorde, 2004, Neurotoxicology.

Both total and phosphorylated tau are increased in Alzheimer's disease

K. Blennow, H. Vanderstichele, M. Tullberg, 2001, Journal of neurology, neurosurgery, and psychiatry.

Regulation of the pituitary 5 alpha-reductase activity by gonadotropin releasing hormone and testosterone in the adult male rat.

H. Vanderstichele, W. Eechaute, E. Lacroix, 1990, Journal of steroid biochemistry.

Bovine preantral follicles and activin: immunohistochemistry for activin and activin receptor and the effect of bovine activin A in vitro.

H. Vanderstichele, J. Beckers, R. van den Hurk, 1997, Theriogenology.

Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition

H. Vanderstichele, E. Mandelkow, M. Staufenbiel, 2017, Alzheimer's & Dementia.

CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease

K. Blennow, H. Vanderstichele, L. Minthon, 2016, Annals of clinical and translational neurology.

Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease

P. Worley, D. Salmon, D. Galasko, 2019, Alzheimer's & dementia.

Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology

W. M. van der Flier, P. Scheltens, F. Barkhof, 2020, Alzheimer's Research & Therapy.

Highly specific and ultrasensitive plasma test detects Abeta(1–42) and Abeta(1–40) in Alzheimer’s disease

P. Scheltens, H. Vanderstichele, C. Teunissen, 2020, Scientific Reports.

Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment

H. Vanderstichele, E. Vanmechelen, C. Teunissen, 2019, Neurology and Therapy.

Development of a Specific Diagnostic Test for Measurement of β-Amyloid (1-42) [βA4(l-42)] in CSF

K. Blennow, H. Vanderstichele, E. Vanmechelen, 1998 .

Onset of Preclinical Alzheimer Disease in Monozygotic Twins

P. Scheltens, P. Visser, H. Vanderstichele, 2021, Annals of neurology.

Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.

K. Blennow, B. Winblad, H. Vanderstichele, 2001, Archives of neurology.

The Effect of Simvastatin Treatment on the Amyloid Precursor Protein and Brain Cholesterol Metabolism in Patients with Alzheimer’s Disease

K. Blennow, H. Vanderstichele, E. Vanmechelen, 2005, Dementia and Geriatric Cognitive Disorders.

Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization

K. Blennow, H. Vanderstichele, E. Vanmechelen, 2000, Neuroscience Letters.

Plasma Amyloid-Beta Levels in a Pre-Symptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy Pedigree: A Cross-Sectional and Longitudinal Investigation

A. Fagan, J. Morris, G. Hankey, 2021, International journal of molecular sciences.

C-Reactive Protein, Plasma Amyloid-&bgr; Levels, and Their Interaction With Magnetic Resonance Imaging Markers

O. Franco, H. Vanderstichele, W. Niessen, 2018, Stroke.

The global Alzheimer's Association round robin study on plasma amyloid β methods

James G. Bollinger, K. Blennow, A. Nakamura, 2021, Alzheimer's & dementia.

Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid Aβ42 and the Ratios of Aβ Isoforms Using Low Protein Binding Tubes

H. Vanderstichele, O. Hansson, S. Janelidze, 2016, Journal of Alzheimer's disease : JAD.

Validation of a multiplex assay for simultaneous quantification of amyloid-β peptide species in human plasma with utility for measurements in studies of Alzheimer's disease therapeutics.

H. Vanderstichele, R. Dean, F. Martényi, 2012, Journal of Alzheimer's disease : JAD.

No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF

K. Blennow, H. Vanderstichele, L. Parnetti, 2016, Molecular Neurodegeneration.

Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

Leslie M. Shaw, Kaj Blennow, Hugo Vanderstichele, 2012, Alzheimer's & Dementia.

Risk of Alzheimer's disease biological misdiagnosis linked to cerebrospinal collection tubes.

H. Vanderstichele, S. Lehmann, J. Touchon, 2012, Journal of Alzheimer's disease : JAD.

Sensus Protocol That Specifically Links Cutoff Values to given Sam- Pling Tubes and Handling/analyti- Cal Protocols. Pierre Krolak-salmon Arnaud Coudreuse Diurnal Plasma Concentrations of Natriuretic Propeptides in Healthy Young Males

H. Vanderstichele, S. Lehmann, J. Touchon, 2012 .

Improved protocol for measurement of plasma β-amyloid in longitudinal evaluation of Alzheimer’s Disease Neuroimaging Initiative study patients

J. Trojanowski, M. Korecka, L. Shaw, 2012, Alzheimer's & Dementia.

Core Alzheimer’s disease cerebrospinal fluid biomarker assays are not affected by aspiration or gravity drip extraction methods

H. Vanderstichele, R. Martins, C. Masters, 2021, Alzheimer's research & therapy.

Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1–42)/Aβ(1–40)

H. Vanderstichele, O. Hansson, S. Janelidze, 2017, Alzheimer's Research & Therapy.

Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study.

P. Visser, H. Vanderstichele, M. Tsolaki, 2017, Journal of Alzheimer's disease : JAD.

Performance Evaluation of an Automated ELISA System for Alzheimer's Disease Detection in Clinical Routine.

P. Calabresi, H. Vanderstichele, L. Parnetti, 2016, Journal of Alzheimer's disease : JAD.

Roadblocks for integration of novel biomarker concepts into clinical routine: the peptoid approach

H. Vanderstichele, T. Kodadek, 2014, Alzheimer's Research & Therapy.

Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology.

A. Fagan, M. Mintun, J. Morris, 2011, Archives of neurology.

Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter study

F. Jessen, H. Vanderstichele, P. Lewczuk, 2008, Neurobiology of Aging.

Roadblocks for integration of novel biomarker concepts into clinical routine: the peptoid approach

H. Vanderstichele, T. Kodadek, 2014, Alzheimer's Research & Therapy.

Alzheimer disease biomarker testing in cerebrospinal fluid: a method to harmonize assay platforms in the absence of an absolute reference standard.

K. Blennow, L. Shaw, H. Vanderstichele, 2013, Clinical chemistry.

Analytical aspects of molecular Alzheimer's disease biomarkers.

L. Shaw, H. Vanderstichele, E. Vanmechelen, 2012, Biomarkers in medicine.

Alzheimers disease biomarkers: from concept to clinical utility

P. Deyn, J. Trojanowski, L. Shaw, 2008 .

How to handle adsorption of cerebrospinal fluid amyloid β (1–42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the Aβ42/Aβ40 ratio

H. Vanderstichele, S. Engelborghs, C. Teunissen, 2017, Alzheimer's & Dementia.

The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers

Giovanni B. Frisoni, José Luis Molinuevo, Aase Handberg, 2011, Alzheimer's & Dementia.

Commutability of the certified reference materials for the standardization of β-amyloid 1-42 assay in human cerebrospinal fluid: lessons for tau and β-amyloid 1-40 measurements

K. Blennow, H. Vanderstichele, R. Umek, 2018, Clinical chemistry and laboratory medicine.

Prospective longitudinal course of cognition in older subjects with mild parkinsonian signs

H. Vanderstichele, D. Berg, C. Schulte, 2016, Alzheimer's Research & Therapy.

Cerebrospinal fluid neurogranin in Alzheimer’s disease studies: are immunoassay results interchangeable?

K. Blennow, H. Vanderstichele, E. Vanmechelen, 2021, Clinical chemistry and laboratory medicine.

CSF levels of tau, β-amyloid1–42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging

K. Blennow, H. Vanderstichele, L. Minthon, 2000, Journal of Neural Transmission.

Plasma Amyloid-β Levels, Cerebral Small Vessel Disease, and Cognition: The Rotterdam Study.

H. Vanderstichele, W. Niessen, C. V. van Duijn, 2017, Journal of Alzheimer's disease : JAD.

Amyloid β peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing

F. Jessen, P. Falkai, I. Heuser, 2010, Experimental Neurology.

The influence of matrix type, diurnal rhythm and sample collection and processing on the measurement of plasma β-amyloid isoforms using the INNO-BIA plasma Aβ forms multiplex assay

E. Siemers, H. Vanderstichele, R. Dean, 2009, The journal of nutrition, health & aging.

Evolution of Aβ42 and Aβ40 levels and Aβ42/Aβ40 ratio in plasma during progression of Alzheimer’s disease: A multicenter assessment

K. Blennow, H. Vanderstichele, P. Lewczuk, 2009 .

Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample.

K. Blennow, B. Winblad, H. Vanderstichele, 1999, Neurology.

Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition.

P. Visser, H. Vanderstichele, D. Devanand, 2017, Journal of Alzheimer's disease : JAD.

Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia

P. Calabresi, H. Vanderstichele, S. Engelborghs, 2017, Alzheimer's Research & Therapy.

No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF

K. Blennow, H. Vanderstichele, L. Parnetti, 2016, Molecular Neurodegeneration.

Alzheimer disease Cerebrospinal Fluid biomarker in Cognitively Normal Subjects : Multicenter 1 Study 2

Sebastiaan, Kaj, William T. Hu, 2015 .

Cerebrospinal fluid levels of total‐tau, phospho‐tau and Aβ42 predicts development of Alzheimer's disease in patients with mild cognitive impairment

Kaj Blennow, Hugo Vanderstichele, Eugeen Vanmechelen, 2003 .

Cerebrospinal fluid τ and β-amyloid(1-42) in dementia disorders

Kaj Blennow, Hugo Vanderstichele, Lennart Minthon, 2001, Mechanisms of Ageing and Development.

Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia.

H. Vanderstichele, S. Engelborghs, E. Vanmechelen, 2012, Journal of Alzheimer's disease : JAD.

Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment

K. Blennow, B. Winblad, H. Vanderstichele, 1999, Neuroscience Letters.

Validation of ELISA methods for quantification of total tau and phosporylated-tau181 in human cerebrospinal fluid with measurement in specimens from two Alzheimer's disease studies.

E. Siemers, H. Vanderstichele, R. Dean, 2011, Journal of Alzheimer's disease : JAD.

Increased total-Tau levels in cerebrospinal fluid of pediatric hydrocephalus and brain tumor patients.

H. Vanderstichele, R. Pieters, S. V. Van Gool, 2008, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

Differences and similarities between two frequently used assays for amyloid beta 42 in cerebrospinal fluid.

P. Scheltens, H. Vanderstichele, Y. Pijnenburg, 2005, Clinical chemistry.

First amyloid β1‐42 certified reference material for re‐calibrating commercial immunoassays

Erin E. Chambers, K. Blennow, M. Quaglia, 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.

Sex-specific associations with cerebrospinal fluid biomarkers in dementia with Lewy bodies

W. M. van der Flier, P. Scheltens, H. Vanderstichele, 2020, Alzheimer's Research & Therapy.

Unaltered plasma levels of beta-amyloid(1-40) and beta-amyloid(1-42) upon stimulation of human platelets.

K. Blennow, H. Vanderstichele, E. Vanmechelen, 2003, Dementia and geriatric cognitive disorders.

Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment.

Kaj Blennow, Hugo Vanderstichele, Eugeen Vanmechelen, 2003, Acta neurologica Scandinavica. Supplementum.

Association of CSF apolipoprotein E, Aβ42 and cognition in Alzheimer’s disease

H. Vanderstichele, A. Kurz, M. Riemenschneider, 2002, Neurobiology of Aging.

Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.

H. Vanderstichele, R. Martins, C. Masters, 2017, Journal of Alzheimer's disease : JAD.

Amino-Truncated β-Amyloid42 Peptides in Cerebrospinal Fluid and Prediction of Progression of Mild Cognitive Impairment

Anders Wallin, Annika Olsson, Kaj Blennow, 2005 .

PHOSPHO-TAU (181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies

K. Blennow, H. Vanderstichele, H. Hampel, 2006 .

Amino-Truncated-Amyloid 42 Peptides in Cerebrospinal Fluid and Prediction of Progression of Mild Cognitive Impairment

K. Blennow, H. Vanderstichele, E. Vanmechelen, 2005 .

Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer’s disease

H. Vanderstichele, P. Dupont, R. Vandenberghe, 2015, Alzheimer's Research & Therapy.

CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer’s disease

K. Blennow, H. Vanderstichele, E. Vanmechelen, 2020, Alzheimer's Research & Therapy.

Prospective longitudinal course of cognition in older subjects with mild parkinsonian signs

H. Vanderstichele, D. Berg, C. Schulte, 2016, Alzheimer's Research & Therapy.

Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease

K. Blennow, H. Vanderstichele, D. Small, 2003, Journal of neuroscience research.

The certification of Amyloid β 1-42 in CSF in ERM ®-DA 480 / IFCC , ERM ®-DA 481 / IFCC and ERM ®-DA 482 / IFCC

Erin E. Chambers, K. Blennow, M. Quaglia, 2017 .

Cerebrospinal Fluid Total and Phosphorylated α-Synuclein in Patients with Creutzfeldt–Jakob Disease and Synucleinopathy

J. Trojanowski, V. Lee, H. Vanderstichele, 2018, Molecular Neurobiology.

Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42.

Kevin Mills, Henrik Zetterberg, Niklas Mattsson, 2012, Biomarkers in medicine.

Neurofilament ELISA validation.

Bernhard Hemmer, Gavin Giovannoni, Johannes Kornhuber, 2010, Journal of immunological methods.

Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1–42)/Aβ(1–40)

H. Vanderstichele, O. Hansson, S. Janelidze, 2017, Alzheimer's Research & Therapy.

Evaluation of CSF biomarkers for axonal and neuronal degeneration, gliosis, and β-amyloid metabolism in Alzheimer's disease

K. Blennow, H. Vanderstichele, E. Vanmechelen, 2001, Journal of neurology, neurosurgery, and psychiatry.

Cerebrospinal fluid collection tubes: a critical issue for Alzheimer disease diagnosis.

H. Vanderstichele, J. Touchon, B. Elmoualij, 2012, Clinical chemistry.

Contribution of genetic and environmental factors to the onset of preclinical Alzheimer's disease - a monozygotic twin study

P. Scheltens, P. Visser, H. Vanderstichele, 2020, medRxiv.

Automation on an Open-Access Platform of Alzheimer’s Disease Biomarker Immunoassays

H. Vanderstichele, R. Vandenberghe, J. Tournoy, 2018, SLAS technology.

S1-6 Perspectives on potential biomarkers in blood for Alzheimer diagnosis

K. Blennow, A. Delacourte, H. Vanderstichele, 2005 .

Cerebrospinal beta-amyloid (1–42) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline

H. Vanderstichele, A. Kurz, M. Riemenschneider, 2000, Neuroscience Letters.

Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment.

Anders Wallin, Annika Olsson, Kaj Blennow, 2005, Clinical chemistry.

A PROTOTYPE SIMOA ASSAY QUANTIFYING PLASMA AMYLOID BETA 1-42 AND 1-40 ISOFORMS CAN DIFFERENTIATE PARTICIPANTS WITH AD FROM HEALTHY CONTROL SUBJECTS

P. Scheltens, H. Vanderstichele, C. Teunissen, 2018, Alzheimer's & Dementia.

Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease

K. Blennow, H. Vanderstichele, R. Martins, 2021, Translational Psychiatry.

The Alzheimer’s Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans

M. Weiner, R. Petersen, J. Trojanowski, 2015, Alzheimer's & Dementia.

Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia

P. Calabresi, H. Vanderstichele, S. Engelborghs, 2017, Alzheimer's Research & Therapy.

PERFORMANCE EVALUATION OF NEW ABSORBANCE-BASED ELISAS FOR MEASURING DIFFERENT ALPHA-SYNUCLEIN (A-SYN) SPECIES IN CSF AND PLASMA

J. Trojanowski, V. Lee, H. Vanderstichele, 2016, Alzheimer's & Dementia.

The confidence level of established cut-off values for CSF Alzheimer's disease-specific biomarkers

H. Vanderstichele, T. Burzykowski, E. Coart, 2015, Alzheimer's & Dementia.

EFFECT OF PRE-ANALYTICAL FACTORS ON AD BIOMARKER LEVELS IN CSF

H. Vanderstichele, S. Engelborghs, P. Deyn, 2011 .

Aging Increased Amyloid Peptide and Caused Amyloid Plaques in Brain of Old APP/V717I Transgenic Mice by a Different Mechanism than Mutant Presenilin1

H. Vanderstichele, F. Checler, F. van Leuven, 2000, The Journal of Neuroscience.

Title: The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau

J. Molinuevo, H. Vanderstichele, R. Umek, 2021 .

Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people.

J. Trojanowski, K. Blennow, L. Shaw, 2010, Archives of neurology.

Influence of neonatal androgenization on the testicular steroidogenesis in the adult rat.

H. Vanderstichele, I. Leusen, W. Eechaute, 1987, Journal of steroid biochemistry.

Amyloid β peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing

I. Heuser, H. Vanderstichele, P. Lewczuk, 2010, Experimental Neurology.

Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology.

A. Fagan, M. Mintun, D. Holtzman, 2011, Archives of neurology.

Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition.

P. Visser, H. Vanderstichele, M. Tsolaki, 2017, Journal of Alzheimer's disease : JAD.

Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42.

K. Blennow, M. Carrillo, H. Soares, 2012, Biomarkers in medicine.

The global Alzheimer's Association round robin study on plasma The global Alzheimer's Association round robin study on plasma amyloid β methods amyloid methods

K. Blennow, A. Nakamura, M. Korecka, 2022 .